You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Addex raises CHF40M via capital offering
Banking Essentials Newsletter - February Edition
Message in a (Word)Cloud
Six trends shaping the industries and sectors we cover in 2021
Six trends shaping the industries and sectors we cover in 2021
Geneva-based Addex Therapeutics Ltd. completed a CHF40 million capital offering.
The company issued 13,037,577 new shares at CHF3.13 apiece.
Addex intends to use the proceeds to develop its portfolio of drug candidates, including registration studies for lead program dipraglurant, a treatment for Parkinson's disease.